BritishJournalofPharmacology
Correspondence
DOI:10.1111/bph.12494doc.guandang.net
ThemedIssue:MitochondrialPharmacology:Energy,Injury&Beyond
RESEARCHPAPER
Apilotstudyofplasma
metabolomicpatternsfrompatientstreatedwithketamineforbipolar
depression:evidenceforaresponse-relateddifferenceinmitochondrialnetworks
AVillaseñor1,ARamamoorthy2,MSilvadosSantos1,3,MPLorenzo1,GLaje4,5,6,CZarateJr4,CBarbas1andIWWainer2
CenterforMetabolomicsandBioanalysis(CEMBIO),FacultaddeFarmacia,UniversidadCEUSanPablo,Madrid,Spain,2LaboratoryofClinicalInvestigation,IntramuralResearchProgram,NationalInstituteonAging,NationalInstitutesofHealth(NIH),Baltimore,MD,USA,3FacultyofPharmacy,FederalUniversityofMinasGerais,BeloHorizonte,Brazil,4ExperimentalTherapeutics&PathophysiologyBranchIntramuralResearchProgram,NationalInstituteofMentalHealth(NIMH),NIH,Bethesda,MD,USA,5HumanGeneticsBranchandGeneticBasisofMoodandAnxietyDisordersSection,IntramuralResearchProgram,NIMH,NIH,Bethesda,
MD,USA,and6MarylandInstituteforNeuroscienceandDevelopment(MIND),Bethesda,MD,USA
1
IrvingWWainer,LaboratoryofClinicalInvestigation,NationalInstituteonAging,NIH,251BayviewBoulevard,08B133,Baltimore,MD21224,USA.
E-mail:wainerir@grc.nia.nih.gov
----------------------------------------------------------------
Keywords
mitochondrialfunction;fattyacidmetabolism;
pharmacometabolomics;lithium;valproate
----------------------------------------------------------------
Received
8August2013
Revised
14October2013
Accepted
28October2013
BACKGROUNDANDPURPOSE
(R,S)-ketamineproducesrapidandsigni cantantidepressanteffectsinapproximately65%ofpatientssufferingfrom
treatment-resistantbipolardepression(BD).Thegenetic,pharmacologicalandbiochemicaldifferencesbetweenketamine
respondersandnon-respondershavenotbeenidenti ed.Thepurposeofthisstudywastoemployametabolomicsapproach,aglobal,non-targeteddeterminationofendogenousmetabolicpatterns,toidentifypotentialmarkersofketamineresponseandnon-response.
EXPERIMENTALAPPROACH
Plasmasamplesfrom22BDpatientswereanalyzedtoproducemetabolomicpatterns.Thepatientshadreceivedketamineinaplacebo-controlledcrossoverstudyandthesampleswereobtained230minpost-administrationatwhichtimethepatientswerecategorizedasrespondersornon-responders.Matchingplasmasamplesfromtheplaceboarmofthestudywerealsoanalysed.Duringthestudy,thepatientsweremaintainedoneitherlithiumorvalproate.
KEYRESULTS
Themetabolomicpatternsweresigni cantlydifferentbetweenthepatientsmaintainedonlithiumandthosemaintainedonvalproate,irrespectiveofresponsetoketamine.Inthepatientsmaintainedonlithium,18biomarkerswereidenti ed.Inresponders,lysophosphatidylethanolamines(4)andlysophosphatidylcholines(9)wereincreasedrelativetonon-responders.
CONCLUSIONSANDIMPLICATIONS
Theresultsindicatethatthedifferencesbetweenpatientswhorespondtoketamineandthosewhodonotaredueto
alterationsinthemitochondrialβ-oxidationoffattyacids.Thesedifferenceswerenotproducedbyketamineadministration.Thedataindicatethatpretreatmentmetabolomicsscreeningmaybeaguidetothepredictionofresponseandapotentialapproachtotheindividualizationofketamine

therapy.
2230BritishJournalofPharmacology(2014)1712230–2242
©2013TheBritishPharmacologicalSociety
热门文档